NCT00137761

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

A Phase II Study of Docetaxel in Combination With ZD 1839 (IRESSA) in Previously Treated Patients With Metastatic Pancreatic Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out what activity the combination of docetaxel and Iressa have against metastatic pancreatic cancer.

Detailed description

Iressa will be taken orally once daily without interruption. Docetaxel will be administered intravenously once weekly for two out of every three weeks. Patients will also receive dexamethasone the night prior, morning of, and the evening after docetaxel treatment to help prevent an allergic reaction. Every week that chemotherapy is given, blood tests and vital signs will be taken. After the first 6 weeks of therapy a CT scan (or other radiological procedure) will be done to assess the progress of the disease. If the cancer is responding to the treatment and no unacceptable side effects have occured, treatment with Iressa and docetaxel will continue. CT scans (or other radiological procedure) will be performed at week 12 and every 9 weeks thereafter to monitor the progress of the disease.

Conditions

• Metastatic Pancreatic Carcinoma

Interventions

Type	Name	Description
DRUG	ZD 1839	Taken orally once daily
DRUG	Docetaxel	Given intravenously once weekly for 2 out of 3 weeks

Timeline

• Start date: 2004-10-01
• Primary completion: 2007-06-01
• Completion: 2009-03-01
• First posted: 2005-08-30
• Last updated: 2009-11-02

Locations

3 sites across 1 country: United States